Titlebook: Melanoma in Clinical Practice; Rhoda M. Alani,Debjani Sahni Book 2021 Springer Nature Switzerland AG 2021 Melanoma.Immunotherapy.Biomarker

HBA1C

書目名稱Melanoma in Clinical Practice影響因子(影響力)




書目名稱Melanoma in Clinical Practice影響因子(影響力)學(xué)科排名




書目名稱Melanoma in Clinical Practice網(wǎng)絡(luò)公開度




書目名稱Melanoma in Clinical Practice網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Melanoma in Clinical Practice被引頻次




書目名稱Melanoma in Clinical Practice被引頻次學(xué)科排名




書目名稱Melanoma in Clinical Practice年度引用




書目名稱Melanoma in Clinical Practice年度引用學(xué)科排名




書目名稱Melanoma in Clinical Practice讀者反饋




書目名稱Melanoma in Clinical Practice讀者反饋學(xué)科排名

CLIFF

乏味

墻壁

Adjuvant Systemic Therapy for Stage III Melanomahile both adjuvant BRAF/MEK-targeted therapy and checkpoint inhibitor therapy have been shown to improve the outcome of stage III patients, a 1-year course of checkpoint inhibitor therapy is commonly considered the standard of care for most stage III patients.

老人病學(xué)

Book 2021sis, treatment and prevention of melanoma. It features easy to digest instructional text that describes a variety of techniques for detecting?and staging melanoma including total body photography. Surgical, radiation and systemic therapy treatment options as well as prevention strategies are also co

熟練

Epidemiology of MelanomaSA, its mortality finally seems to be leveling off in many places. Lessons learned from one country may be useful to others, as primary and secondary prevention campaigns are tried. Here, we discuss current patterns in melanoma incidence and mortality, as well as trends in tumor thickness and the most common melanoma subtypes.

AVOW

Evolution of Neoadjuvant Therapy in Melanomae have been able to better define the extent of surgical resection necessary for improved disease-free and overall survival. This chapter will review the benefits of neoadjuvant combination therapy, monotherapy, targeted therapy and how each is best achieved in concert with surgical resection.

CRAMP

狗窩

DALLY

Adjuvant Radiation Therapy for Stage III Melanomaprimary adjuvant treatment modality in Stage III and Stage IV disease. In the era of immunotherapy, we discuss the role and benefit of adjuvant RT. We also discuss the role of RT in desmoplastic melanoma.